AGER and major depressive disorder: N-3 PUFAs may modulate the release of these DAMPs by interfering with their binding to their receptors such as toll-like receptors (TLRs) and receptor for advanced glycation end product (RAGE), thereby mitigating the activation of inflammatory responses linked to depression [31].